Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage
- Study conducted in collaboration with
MITshowed that triamcinolone acetonide had protective effects on inflamed and/or injured cartilage in an established preclinical model
- Data presented in “late breaker” session at the recent 2019
Orthopaedic Research SocietyAnnual Meeting
The new data were unveiled in a “late breaker” poster presentation, “Dose-Dependent Chondroprotective Effects of Triamcinolone Acetonide on Inflamed and Injured Cartilage Using an In Vitro Model” (#2202), at the recently held
“In light of prior conflicting data about the impact of corticosteroids on cartilage structure, these data are particularly compelling because they suggest that, at the low doses used in this 1-week in vitro study, TA does not induce cartilage matrix degradation in ‘normal’ cartilage,” said Professor Grodzinsky. “Furthermore, these data indicate that TA can dose dependently protect against, and even restore, the decrease in matrix biosynthesis caused by inflammatory mediators in the synovial fluid combined with injurious compression of cartilage.”
Key Findings from the Study Relative to OA:
- In an in vitro model, the administration of pro-inflammatory cytokines and/or mechanical injury to cartilage explants resulted in a reduction of cartilage matrix biosynthesis and an increase in cartilage matrix breakdown.
- The administration of TA in inflamed and/or injured cartilage tissue had protective effects, such as restoration of cartilage matrix biosynthesis and prevention of cartilage matrix breakdown, and no detrimental effects were observed at any dose in inflamed or injured cartilage.
The study was funded by
About Osteoarthritis (OA) of the Knee
OA, also known as degenerative joint disease, affects more than 30 million Americans and accounts for more than
This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this press release regarding matters that are not historical facts, including but not limited to statements relating to the future of Flexion, the potential impact of triamcinolone acetonide on inflamed and/or injured cartilage, and expected increases in the prevalence of OA, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the fact that preclinical study results may not be predictive of results in clinical trials or from commercial use of a product; risks associated with commercializing new pharmaceutical products in
- Lu YCS, Evans CH, Grodzinsky AJ. Effects of short-term glucocorticoid treatment on changes in cartilage matrix degeneration and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis Res Ther. 2011; 13(5): R142
- Kumar A et al. Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis. Osteoarthritis Cartilage. 2015;23(1):151-160
Vice President, Corporate Communications & Investor Relations
Manager, Corporate Communications
Source: Flexion Therapeutics, Inc.